EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Rubius Exec Dowden Departs for Entrada Chief Operating Officer Post

Xconomy Boston — 

Entrada Therapeutics has appointed Nathan Dowden to serve as its chief operating officer. He joins Boston-based Entrada from Rubius Therapeutics, where he was senior vice president of strategy and corporate development. Entrada is developing drugs that that use cell-penetrating peptides to bring a therapy into a cell. Last year, the biotech raised $59 million in Series A financing.